ALPHANATE offers savings when treating patients with von Willebrand disease (VWD)

Save with ALPHANATE

Calculate how much you can save using ALPHANATE for your patients with VWD.

Calculate Your Savings Now

Download the cost calculator worksheet to see how much
ALPHANATE can save you.


ALPHANATE is the only FVIII/VWF product for von Willebrand disease priced in FVIII units

ALPHANATE lists both the FVIII and von Willebrand factor ristocetin cofactor (VWF:RCo) international units on every vial produced, so you know exactly how much you are infusing.


Example pricing comparison for treatment of VWD*

List price VWF:RCo : FVIII Price per VWF:RCo IU
ALPHANATE $0.75/ FVIII IU 1.3:1 $0.58
Competitor $0.75/VWF:RCo IU $0.75
ALPHANATE
List price $0.75/ FVIII IU
VWF:RCo : FVIII 1.3:1
Price per VWF:RCo IU $0.58
Competitor
List price $0.75/VWF:RCo IU
VWF:RCo : FVIII
Price per VWF:RCo IU $0.75

ALPHANATE dosing for VWD

Dosing in minor surgery/bleeding1

VWF:RCo Target FVIII:FC activity levels
Preoperative/preprocedure dose Adults:60 IU VWF:RCo/kg body weight
Pediatrics:75 IU VWF:RCo/kg body weight
40 to 50 IU/dL
Maintenance dose Adults:40 to 60 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for 1 to 3 days
Pediatrics:50 to 75 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for 1 to 3 days
40 to 50 IU/dL
Safety monitoring Peak and trough at least once daily Peak and trough at least once daily
Therapeutic goal (trough) >50 IU/dL >50 IU/dL
Safety parameter Should not exceed 150 IU/dL Should not exceed 150 IU/dL
Preoperative/preprocedure dose
VWF:RCo Adults:60 IU VWF:RCo/kg body weight
Pediatrics:75 IU VWF:RCo/kg body weight
Target FVIII:FC activity levels 40 to 50 IU/dL
Maintenance dose
VWF:RCo Adults:40 to 60 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for 1 to 3 days
Pediatrics:50 to 75 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for 1 to 3 days
Target FVIII:FC activity levels 40 to 50 IU/dL
Safety monitoring
VWF:RCo Peak and trough at least once daily
Target FVIII:FC activity levels Peak and trough at least once daily
Therapeutic goal (trough)
VWF:RCo >50 IU/dL
Target FVIII:FC activity levels >50 IU/dL
Safety parameter
VWF:RCo Should not exceed 150 IU/dL
Target FVIII:FC activity levels Should not exceed 150 IU/dL

Dosing in major surgery/bleeding (except type 3 patients undergoing major surgery)1

VWF:RCo Target FVIII:FC activity levels
Preoperative/preprocedure dose Adults: 60 IU VWF:RCo/kg body weight
Pediatrics: 75 IU VWF:RCo/kg body weight
100 IU/dL
Maintenance dose Adults:40 to 60 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for at least 3 to 7 days 
Pediatrics:50 to 75 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for at least 3 to 7 days 
100 IU/dL
Safety monitoring Peak and trough at least once daily Peak and trough at least once daily
Therapeutic goal (trough) >50 IU/dL >50 IU/dL
Safety parameter Should not exceed 150 IU/dL Should not exceed 150 IU/dL
Preoperative/preprocedure dose
VWF:RCo Adults: 60 IU VWF:RCo/kg body weight
Pediatrics: 75 IU VWF:RCo/kg body weight
Target FVIII:FC activity levels 100 IU/dL
Maintenance dose
VWF:RCo Adults:40 to 60 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for at least 3 to 7 days 
Pediatrics:50 to 75 IU VWF:RCo/kg body weight at 8- to 12-hour intervals as clinically needed for at least 3 to 7 days 
Target FVIII:FC activity levels 100 IU/dL
Safety monitoring
VWF:RCo Peak and trough at least once daily
Target FVIII:FC activity levels Peak and trough at least once daily
Therapeutic goal (trough)
VWF:RCo >50 IU/dL
Target FVIII:FC activity levels >50 IU/dL
Safety parameter
VWF:RCo Should not exceed 150 IU/dL
Target FVIII:FC activity levels Should not exceed 150 IU/dL

Make the most of ALPHANATE treatment

The value of ALPHANATE

Download an educational booklet demonstrating the value of ALPHANATE in both hemophilia A and VWD patients.
Download PDF


Optimizing treatment with WAPPS-Hemo

Discover how WAPPS-Hemo can help you optimize care for your hemophilia A patients.
Learn more 


Have any questions?

Our specialty sales representative assigned to your territory will be glad to contact or visit you to answer any questions about ALPHANATE.
Request a representative


Indications

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery
Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.